vsample as the dose of Requip is individually titrated to clinical therapeutic response and tolerability . Pharmacokinetic trials conducted in patients demonstrated that oral clearance of ropinirole is reduced by 15% in patients older than 65 years compared with younger patients [see Clinical Pharmacology (12.3)] . In flexible-dose clinical trials of extended-release ropinirole for Parkinson s disease quite a few
obsessed on tients have not been established. Geriatric Use Dose adjustment is not necessary in elderly (65 years and older) patients usual
EmoticonEmoticon